

United States Hospital-acquired Pneumonia (HAP) Drugs Market Report 2017

<https://marketpublishers.com/r/U241E08D461EN.html>

Date: November 2017

Pages: 111

Price: US\$ 3,800.00 (Single User License)

ID: U241E08D461EN

Abstracts

In this report, the United States Hospital-acquired Pneumonia (HAP) Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:

The West

Southwest

The Middle Atlantic

New England

The South

The Midwest

with sales (volume), revenue (value), market share and growth rate of Hospital-acquired Pneumonia (HAP) Drugs in these regions, from 2012 to 2022 (forecast).

United States Hospital-acquired Pneumonia (HAP) Drugs market competition by top manufacturers/players, with Hospital-acquired Pneumonia (HAP) Drugs sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top

players including

Pfizer

GlaxoSmithKline

Merck

Mylan

Novartis

Teva Pharmaceutical Industries

AstraZeneca

Arsanis

Combioxin

Shinogi

Sun Pharmaceutical Industries

The Medicines Company

Theravance Biopharma

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

Antibacterial

Antiviral

Antifungal

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including

Hospitals

Clinics

Other

If you have any special requirements, please let us know and we will offer you the report as you want.

Contents

United States Hospital-acquired Pneumonia (HAP) Drugs Market Report 2017

1 HOSPITAL-ACQUIRED PNEUMONIA (HAP) DRUGS OVERVIEW

- 1.1 Product Overview and Scope of Hospital-acquired Pneumonia (HAP) Drugs
- 1.2 Classification of Hospital-acquired Pneumonia (HAP) Drugs by Product Category
 - 1.2.1 United States Hospital-acquired Pneumonia (HAP) Drugs Market Size (Sales Volume) Comparison by Type (2012-2022)
 - 1.2.2 United States Hospital-acquired Pneumonia (HAP) Drugs Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
 - 1.2.3 Antibacterial
 - 1.2.4 Antiviral
 - 1.2.5 Antifungal
- 1.3 United States Hospital-acquired Pneumonia (HAP) Drugs Market by Application/End Users
 - 1.3.1 United States Hospital-acquired Pneumonia (HAP) Drugs Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
 - 1.3.2 Hospitals
 - 1.3.3 Clinics
 - 1.3.4 Other
- 1.4 United States Hospital-acquired Pneumonia (HAP) Drugs Market by Region
 - 1.4.1 United States Hospital-acquired Pneumonia (HAP) Drugs Market Size (Value) Comparison by Region (2012-2022)
 - 1.4.2 The West Hospital-acquired Pneumonia (HAP) Drugs Status and Prospect (2012-2022)
 - 1.4.3 Southwest Hospital-acquired Pneumonia (HAP) Drugs Status and Prospect (2012-2022)
 - 1.4.4 The Middle Atlantic Hospital-acquired Pneumonia (HAP) Drugs Status and Prospect (2012-2022)
 - 1.4.5 New England Hospital-acquired Pneumonia (HAP) Drugs Status and Prospect (2012-2022)
 - 1.4.6 The South Hospital-acquired Pneumonia (HAP) Drugs Status and Prospect (2012-2022)
 - 1.4.7 The Midwest Hospital-acquired Pneumonia (HAP) Drugs Status and Prospect (2012-2022)
- 1.5 United States Market Size (Value and Volume) of Hospital-acquired Pneumonia (HAP) Drugs (2012-2022)

1.5.1 United States Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2012-2022)

1.5.2 United States Hospital-acquired Pneumonia (HAP) Drugs Revenue and Growth Rate (2012-2022)

2 UNITED STATES HOSPITAL-ACQUIRED PNEUMONIA (HAP) DRUGS MARKET COMPETITION BY PLAYERS/SUPPLIERS

2.1 United States Hospital-acquired Pneumonia (HAP) Drugs Sales and Market Share of Key Players/Suppliers (2012-2017)

2.2 United States Hospital-acquired Pneumonia (HAP) Drugs Revenue and Share by Players/Suppliers (2012-2017)

2.3 United States Hospital-acquired Pneumonia (HAP) Drugs Average Price by Players/Suppliers (2012-2017)

2.4 United States Hospital-acquired Pneumonia (HAP) Drugs Market Competitive Situation and Trends

2.4.1 United States Hospital-acquired Pneumonia (HAP) Drugs Market Concentration Rate

2.4.2 United States Hospital-acquired Pneumonia (HAP) Drugs Market Share of Top 3 and Top 5 Players/Suppliers

2.4.3 Mergers & Acquisitions, Expansion in United States Market

2.5 United States Players/Suppliers Hospital-acquired Pneumonia (HAP) Drugs Manufacturing Base Distribution, Sales Area, Product Type

3 UNITED STATES HOSPITAL-ACQUIRED PNEUMONIA (HAP) DRUGS SALES (VOLUME) AND REVENUE (VALUE) BY REGION (2012-2017)

3.1 United States Hospital-acquired Pneumonia (HAP) Drugs Sales and Market Share by Region (2012-2017)

3.2 United States Hospital-acquired Pneumonia (HAP) Drugs Revenue and Market Share by Region (2012-2017)

3.3 United States Hospital-acquired Pneumonia (HAP) Drugs Price by Region (2012-2017)

4 UNITED STATES HOSPITAL-ACQUIRED PNEUMONIA (HAP) DRUGS SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (PRODUCT CATEGORY) (2012-2017)

4.1 United States Hospital-acquired Pneumonia (HAP) Drugs Sales and Market Share by Type (Product Category) (2012-2017)

4.2 United States Hospital-acquired Pneumonia (HAP) Drugs Revenue and Market Share by Type (2012-2017)

4.3 United States Hospital-acquired Pneumonia (HAP) Drugs Price by Type (2012-2017)

4.4 United States Hospital-acquired Pneumonia (HAP) Drugs Sales Growth Rate by Type (2012-2017)

5 UNITED STATES HOSPITAL-ACQUIRED PNEUMONIA (HAP) DRUGS SALES (VOLUME) BY APPLICATION (2012-2017)

5.1 United States Hospital-acquired Pneumonia (HAP) Drugs Sales and Market Share by Application (2012-2017)

5.2 United States Hospital-acquired Pneumonia (HAP) Drugs Sales Growth Rate by Application (2012-2017)

5.3 Market Drivers and Opportunities

6 UNITED STATES HOSPITAL-ACQUIRED PNEUMONIA (HAP) DRUGS PLAYERS/SUPPLIERS PROFILES AND SALES DATA

6.1 Pfizer

6.1.1 Company Basic Information, Manufacturing Base and Competitors

6.1.2 Hospital-acquired Pneumonia (HAP) Drugs Product Category, Application and Specification

6.1.2.1 Product A

6.1.2.2 Product B

6.1.3 Pfizer Hospital-acquired Pneumonia (HAP) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.1.4 Main Business/Business Overview

6.2 GlaxoSmithKline

6.2.2 Hospital-acquired Pneumonia (HAP) Drugs Product Category, Application and Specification

6.2.2.1 Product A

6.2.2.2 Product B

6.2.3 GlaxoSmithKline Hospital-acquired Pneumonia (HAP) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.2.4 Main Business/Business Overview

6.3 Merck

6.3.2 Hospital-acquired Pneumonia (HAP) Drugs Product Category, Application and Specification

6.3.2.1 Product A

6.3.2.2 Product B

6.3.3 Merck Hospital-acquired Pneumonia (HAP) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.3.4 Main Business/Business Overview

6.4 Mylan

6.4.2 Hospital-acquired Pneumonia (HAP) Drugs Product Category, Application and Specification

6.4.2.1 Product A

6.4.2.2 Product B

6.4.3 Mylan Hospital-acquired Pneumonia (HAP) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.4.4 Main Business/Business Overview

6.5 Novartis

6.5.2 Hospital-acquired Pneumonia (HAP) Drugs Product Category, Application and Specification

6.5.2.1 Product A

6.5.2.2 Product B

6.5.3 Novartis Hospital-acquired Pneumonia (HAP) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.5.4 Main Business/Business Overview

6.6 Teva Pharmaceutical Industries

6.6.2 Hospital-acquired Pneumonia (HAP) Drugs Product Category, Application and Specification

6.6.2.1 Product A

6.6.2.2 Product B

6.6.3 Teva Pharmaceutical Industries Hospital-acquired Pneumonia (HAP) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.6.4 Main Business/Business Overview

6.7 AstraZeneca

6.7.2 Hospital-acquired Pneumonia (HAP) Drugs Product Category, Application and Specification

6.7.2.1 Product A

6.7.2.2 Product B

6.7.3 AstraZeneca Hospital-acquired Pneumonia (HAP) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.7.4 Main Business/Business Overview

6.8 Arsanis

6.8.2 Hospital-acquired Pneumonia (HAP) Drugs Product Category, Application and

Specification

6.8.2.1 Product A

6.8.2.2 Product B

6.8.3 Arsanis Hospital-acquired Pneumonia (HAP) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.8.4 Main Business/Business Overview

6.9 Combioxin

6.9.2 Hospital-acquired Pneumonia (HAP) Drugs Product Category, Application and Specification

6.9.2.1 Product A

6.9.2.2 Product B

6.9.3 Combioxin Hospital-acquired Pneumonia (HAP) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.9.4 Main Business/Business Overview

6.10 Shinogi

6.10.2 Hospital-acquired Pneumonia (HAP) Drugs Product Category, Application and Specification

6.10.2.1 Product A

6.10.2.2 Product B

6.10.3 Shinogi Hospital-acquired Pneumonia (HAP) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.10.4 Main Business/Business Overview

6.11 Sun Pharmaceutical Industries

6.12 The Medicines Company

6.13 Theravance Biopharma

7 HOSPITAL-ACQUIRED PNEUMONIA (HAP) DRUGS MANUFACTURING COST ANALYSIS

7.1 Hospital-acquired Pneumonia (HAP) Drugs Key Raw Materials Analysis

7.1.1 Key Raw Materials

7.1.2 Price Trend of Key Raw Materials

7.1.3 Key Suppliers of Raw Materials

7.1.4 Market Concentration Rate of Raw Materials

7.2 Proportion of Manufacturing Cost Structure

7.2.1 Raw Materials

7.2.2 Labor Cost

7.2.3 Manufacturing Expenses

7.3 Manufacturing Process Analysis of Hospital-acquired Pneumonia (HAP) Drugs

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

- 8.1 Hospital-acquired Pneumonia (HAP) Drugs Industrial Chain Analysis
- 8.2 Upstream Raw Materials Sourcing
- 8.3 Raw Materials Sources of Hospital-acquired Pneumonia (HAP) Drugs Major Manufacturers in 2016
- 8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

- 9.1 Marketing Channel
 - 9.1.1 Direct Marketing
 - 9.1.2 Indirect Marketing
 - 9.1.3 Marketing Channel Development Trend
- 9.2 Market Positioning
 - 9.2.1 Pricing Strategy
 - 9.2.2 Brand Strategy
 - 9.2.3 Target Client
- 9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

- 10.1 Technology Progress/Risk
 - 10.1.1 Substitutes Threat
 - 10.1.2 Technology Progress in Related Industry
- 10.2 Consumer Needs/Customer Preference Change
- 10.3 Economic/Political Environmental Change

11 UNITED STATES HOSPITAL-ACQUIRED PNEUMONIA (HAP) DRUGS MARKET SIZE (VALUE AND VOLUME) FORECAST (2017-2022)

- 11.1 United States Hospital-acquired Pneumonia (HAP) Drugs Sales Volume, Revenue Forecast (2017-2022)
- 11.2 United States Hospital-acquired Pneumonia (HAP) Drugs Sales Volume Forecast by Type (2017-2022)
- 11.3 United States Hospital-acquired Pneumonia (HAP) Drugs Sales Volume Forecast by Application (2017-2022)
- 11.4 United States Hospital-acquired Pneumonia (HAP) Drugs Sales Volume Forecast

by Region (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach

13.1.1 Research Programs/Design

13.1.2 Market Size Estimation

13.1.3 Market Breakdown and Data Triangulation

13.2 Data Source

13.2.1 Secondary Sources

13.2.2 Primary Sources

13.3 Disclaimer

The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Product Picture of Hospital-acquired Pneumonia (HAP) Drugs

Figure United States Hospital-acquired Pneumonia (HAP) Drugs Market Size (K Pcs) by Type (2012-2022)

Figure United States Hospital-acquired Pneumonia (HAP) Drugs Sales Volume Market Share by Type (Product Category) in 2016

Figure Antibacterial Product Picture

Figure Antiviral Product Picture

Figure Antifungal Product Picture

Figure United States Hospital-acquired Pneumonia (HAP) Drugs Market Size (K Pcs) by Application (2012-2022)

Figure United States Sales Market Share of Hospital-acquired Pneumonia (HAP) Drugs by Application in 2016

Figure Hospitals Examples

Table Key Downstream Customer in Hospitals

Figure Clinics Examples

Table Key Downstream Customer in Clinics

Figure Other Examples

Table Key Downstream Customer in Other

Figure United States Hospital-acquired Pneumonia (HAP) Drugs Market Size (Million USD) by Region (2012-2022)

Figure The West Hospital-acquired Pneumonia (HAP) Drugs Revenue (Million USD) and Growth Rate (2012-2022)

Figure Southwest Hospital-acquired Pneumonia (HAP) Drugs Revenue (Million USD) and Growth Rate (2012-2022)

Figure The Middle Atlantic Hospital-acquired Pneumonia (HAP) Drugs Revenue (Million USD) and Growth Rate (2012-2022)

Figure New England Hospital-acquired Pneumonia (HAP) Drugs Revenue (Million USD) and Growth Rate (2012-2022)

Figure The South of US Hospital-acquired Pneumonia (HAP) Drugs Revenue (Million USD) and Growth Rate (2012-2022)

Figure The Midwest Hospital-acquired Pneumonia (HAP) Drugs Revenue (Million USD) and Growth Rate (2012-2022)

Figure United States Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs) and Growth Rate (2012-2022)

Figure United States Hospital-acquired Pneumonia (HAP) Drugs Revenue (Million USD)

and Growth Rate (2012-2022)

Figure United States Hospital-acquired Pneumonia (HAP) Drugs Market Major Players Product Sales Volume (K Pcs) (2012-2017)

Table United States Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs) of Key Players/Suppliers (2012-2017)

Table United States Hospital-acquired Pneumonia (HAP) Drugs Sales Share by Players/Suppliers (2012-2017)

Figure 2016 United States Hospital-acquired Pneumonia (HAP) Drugs Sales Share by Players/Suppliers

Figure 2017 United States Hospital-acquired Pneumonia (HAP) Drugs Sales Share by Players/Suppliers

Figure United States Hospital-acquired Pneumonia (HAP) Drugs Market Major Players Product Revenue (Million USD) (2012-2017)

Table United States Hospital-acquired Pneumonia (HAP) Drugs Revenue (Million USD) by Players/Suppliers (2012-2017)

Table United States Hospital-acquired Pneumonia (HAP) Drugs Revenue Share by Players/Suppliers (2012-2017)

Figure 2016 United States Hospital-acquired Pneumonia (HAP) Drugs Revenue Share by Players/Suppliers

Figure 2017 United States Hospital-acquired Pneumonia (HAP) Drugs Revenue Share by Players/Suppliers

Table United States Market Hospital-acquired Pneumonia (HAP) Drugs Average Price (USD/Pcs) of Key Players/Suppliers (2012-2017)

Figure United States Market Hospital-acquired Pneumonia (HAP) Drugs Average Price (USD/Pcs) of Key Players/Suppliers in 2016

Figure United States Hospital-acquired Pneumonia (HAP) Drugs Market Share of Top 3 Players/Suppliers

Figure United States Hospital-acquired Pneumonia (HAP) Drugs Market Share of Top 5 Players/Suppliers

Table United States Players/Suppliers Hospital-acquired Pneumonia (HAP) Drugs Manufacturing Base Distribution and Sales Area

Table United States Players/Suppliers Hospital-acquired Pneumonia (HAP) Drugs Product Category

Table United States Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs) by Region (2012-2017)

Table United States Hospital-acquired Pneumonia (HAP) Drugs Sales Share by Region (2012-2017)

Figure United States Hospital-acquired Pneumonia (HAP) Drugs Sales Share by Region (2012-2017)

Figure United States Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share by Region in 2016

Table United States Hospital-acquired Pneumonia (HAP) Drugs Revenue (Million USD) and Market Share by Region (2012-2017)

Table United States Hospital-acquired Pneumonia (HAP) Drugs Revenue Share by Region (2012-2017)

Figure United States Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share by Region (2012-2017)

Figure United States Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share by Region in 2016

Table United States Hospital-acquired Pneumonia (HAP) Drugs Price (USD/Pcs) by Region (2012-2017)

Table United States Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs) by Type (2012-2017)

Table United States Hospital-acquired Pneumonia (HAP) Drugs Sales Share by Type (2012-2017)

Figure United States Hospital-acquired Pneumonia (HAP) Drugs Sales Share by Type (2012-2017)

Figure United States Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share by Type in 2016

Table United States Hospital-acquired Pneumonia (HAP) Drugs Revenue (Million USD) and Market Share by Type (2012-2017)

Table United States Hospital-acquired Pneumonia (HAP) Drugs Revenue Share by Type (2012-2017)

Figure Revenue Market Share of Hospital-acquired Pneumonia (HAP) Drugs by Type (2012-2017)

Figure Revenue Market Share of Hospital-acquired Pneumonia (HAP) Drugs by Type in 2016

Table United States Hospital-acquired Pneumonia (HAP) Drugs Price (USD/Pcs) by Types (2012-2017)

Figure United States Hospital-acquired Pneumonia (HAP) Drugs Sales Growth Rate by Type (2012-2017)

Table United States Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs) by Application (2012-2017)

Table United States Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share by Application (2012-2017)

Figure United States Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share by Application (2012-2017)

Figure United States Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share by

Application in 2016

Table United States Hospital-acquired Pneumonia (HAP) Drugs Sales Growth Rate by Application (2012-2017)

Figure United States Hospital-acquired Pneumonia (HAP) Drugs Sales Growth Rate by Application (2012-2017)

Table Pfizer Basic Information List

Table Pfizer Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)

Figure Pfizer Hospital-acquired Pneumonia (HAP) Drugs Sales Growth Rate (2012-2017)

Figure Pfizer Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share in United States (2012-2017)

Figure Pfizer Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share in United States (2012-2017)

Table GlaxoSmithKline Basic Information List

Table GlaxoSmithKline Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)

Figure GlaxoSmithKline Hospital-acquired Pneumonia (HAP) Drugs Sales Growth Rate (2012-2017)

Figure GlaxoSmithKline Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share in United States (2012-2017)

Figure GlaxoSmithKline Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share in United States (2012-2017)

Table Merck Basic Information List

Table Merck Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)

Figure Merck Hospital-acquired Pneumonia (HAP) Drugs Sales Growth Rate (2012-2017)

Figure Merck Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share in United States (2012-2017)

Figure Merck Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share in United States (2012-2017)

Table Mylan Basic Information List

Table Mylan Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)

Figure Mylan Hospital-acquired Pneumonia (HAP) Drugs Sales Growth Rate (2012-2017)

Figure Mylan Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share in United States (2012-2017)

Figure Mylan Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share in United States (2012-2017)

Table Novartis Basic Information List

Table Novartis Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)

Figure Novartis Hospital-acquired Pneumonia (HAP) Drugs Sales Growth Rate (2012-2017)

Figure Novartis Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share in United States (2012-2017)

Figure Novartis Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share in United States (2012-2017)

Table Teva Pharmaceutical Industries Basic Information List

Table Teva Pharmaceutical Industries Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)

Figure Teva Pharmaceutical Industries Hospital-acquired Pneumonia (HAP) Drugs Sales Growth Rate (2012-2017)

Figure Teva Pharmaceutical Industries Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share in United States (2012-2017)

Figure Teva Pharmaceutical Industries Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share in United States (2012-2017)

Table AstraZeneca Basic Information List

Table AstraZeneca Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)

Figure AstraZeneca Hospital-acquired Pneumonia (HAP) Drugs Sales Growth Rate (2012-2017)

Figure AstraZeneca Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share in United States (2012-2017)

Figure AstraZeneca Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share in United States (2012-2017)

Table Arsanis Basic Information List

Table Arsanis Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)

Figure Arsanis Hospital-acquired Pneumonia (HAP) Drugs Sales Growth Rate (2012-2017)

Figure Arsanis Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share in United States (2012-2017)

Figure Arsanis Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share in United States (2012-2017)

Table Combioxin Basic Information List

Table Combioxin Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)

Figure Combioxin Hospital-acquired Pneumonia (HAP) Drugs Sales Growth Rate (2012-2017)

Figure Combioxin Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share in United States (2012-2017)

Figure Combioxin Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share in United States (2012-2017)

Table Shinogi Basic Information List

Table Shinogi Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)

Figure Shinogi Hospital-acquired Pneumonia (HAP) Drugs Sales Growth Rate (2012-2017)

Figure Shinogi Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share in United States (2012-2017)

Figure Shinogi Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share in United States (2012-2017)

Table Sun Pharmaceutical Industries Basic Information List

Table The Medicines Company Basic Information List

Table Theravance Biopharma Basic Information List

Table Production Base and Market Concentration Rate of Raw Material

Figure Price Trend of Key Raw Materials

Table Key Suppliers of Raw Materials

Figure Manufacturing Cost Structure of Hospital-acquired Pneumonia (HAP) Drugs

Figure Manufacturing Process Analysis of Hospital-acquired Pneumonia (HAP) Drugs

Figure Hospital-acquired Pneumonia (HAP) Drugs Industrial Chain Analysis

Table Raw Materials Sources of Hospital-acquired Pneumonia (HAP) Drugs Major Players/Suppliers in 2016

Table Major Buyers of Hospital-acquired Pneumonia (HAP) Drugs

Table Distributors/Traders List

Figure United States Hospital-acquired Pneumonia (HAP) Drugs Sales Volume (K Pcs) and Growth Rate Forecast (2017-2022)

Figure United States Hospital-acquired Pneumonia (HAP) Drugs Revenue (Million USD) and Growth Rate Forecast (2017-2022)

Figure United States Hospital-acquired Pneumonia (HAP) Drugs Price (USD/Pcs) Trend Forecast (2017-2022)

Table United States Hospital-acquired Pneumonia (HAP) Drugs Sales Volume (K Pcs) Forecast by Type (2017-2022)

Figure United States Hospital-acquired Pneumonia (HAP) Drugs Sales Volume (K Pcs)

Forecast by Type (2017-2022)

Figure United States Hospital-acquired Pneumonia (HAP) Drugs Sales Volume (K Pcs)

Forecast by Type in 2022

Table United States Hospital-acquired Pneumonia (HAP) Drugs Sales Volume (K Pcs)

Forecast by Application (2017-2022)

Figure United States Hospital-acquired Pneumonia (HAP) Drugs Sales Volume (K Pcs)

Forecast by Application (2017-2022)

Figure United States Hospital-acquired Pneumonia (HAP) Drugs Sales Volume (K Pcs)

Forecast by Application in 2022

Table United States Hospital-acquired Pneumonia (HAP) Drugs Sales Volume (K Pcs)

Forecast by Region (2017-2022)

Table United States Hospital-acquired Pneumonia (HAP) Drugs Sales Volume Share

Forecast by Region (2017-2022)

Figure United States Hospital-acquired Pneumonia (HAP) Drugs Sales Volume Share

Forecast by Region (2017-2022)

Figure United States Hospital-acquired Pneumonia (HAP) Drugs Sales Volume Share

Forecast by Region in 2022

Table Research Programs/Design for This Report

Figure Bottom-up and Top-down Approaches for This Report

Figure Data Triangulation

Table Key Data Information from Secondary Sources

Table Key Data Information from Primary Sources

I would like to order

Product name: United States Hospital-acquired Pneumonia (HAP) Drugs Market Report 2017

Product link: <https://marketpublishers.com/r/U241E08D461EN.html>

Price: US\$ 3,800.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/U241E08D461EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970